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S U M M A R Y
Objective: The aims of this study were to perform a systematic review and synthesize epidemiological
data on hepatitis C virus (HCV) in the Arabian Gulf countries, and to assess the country-speciﬁc
prevalence among nationals and expatriate populations.
Methods: A systematic review of HCV antibody prevalence and incidence in the Arabian Gulf countries
was conducted, based on the items outlined in the PRISMA statement. Meta-analyses were performed
incorporating inverse variance weighting and using a random-effects model to pool summary estimates
of HCV prevalence among general population groups, for nationals and the entire resident population.
Results: A total of 557 prevalence measures and one incidence measure were identiﬁed for the Arabian
Gulf countries. HCV prevalence among nationals was 0.24% (95% conﬁdence interval (CI) 0.02–0.63) in
the United Arab Emirates (UAE), 0.44% (95% CI 0.29–0.62) in Kuwait, 0.51% (95% CI 0.43–0.59) in Qatar,
and 1.65% (95% CI 1.40–1.91) in Saudi Arabia. No data were available for Bahrain or Oman. Among the
entire resident populations, HCV prevalence was 0.30% (95% CI 0.23–0.38) in Bahrain, 0.41% (95% CI
0.35–0.46) in Oman, 1.06% (95% CI 0.51–1.81) in Qatar, 1.45% (95% CI 0.75–2.34) in Kuwait, 1.63% (95% CI
1.42–1.84) in Saudi Arabia, and 1.64% (95% CI 0.96–2.49) in UAE. A higher prevalence was observed
among expatriate populations such as Egyptians. Among the high-risk populations, HCV prevalence was
as high as 78.6% in the multi-transfused and 74.6% in people who inject drugs.
Conclusions: National-level HCV prevalence in the Arabian Gulf region is comparable to global levels. A
higher prevalence is found in speciﬁc expatriate populations, reﬂecting the prevalence in their countries
of origin. Most exposures appear to occur in high-risk groups and these are often linked to medical care.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The Middle East and North Africa (MENA) region appears to
have the highest prevalence of hepatitis C virus (HCV) infection
worldwide.1,2 A few countries in the region are heavily affected by
HCV, including Egypt with a prevalence of 14.7%3,4 and Pakistan
with a prevalence of 4.8%.5 The scale of the infection burden in the
Arabian Gulf countries remains poorly understood.
Geographically, the Arabian Gulf region encompasses six
countries: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the
United Arab Emirates (UAE). These countries share common socio-
cultural values and economic attributes, and together constitute* Corresponding author. Tel.: +974 4492 8321; fax: +974 4492 8333.
E-mail address: lja2002@qatar-med.cornell.edu (L.J. Abu-Raddad).
http://dx.doi.org/10.1016/j.ijid.2016.03.012
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the Gulf Cooperation Council (GCC), a political and economic union
established in 1981.6 Public health policy and programs are often
designed and implemented at the level of the GCC. GCC countries
are marked by the diversity of their resident populations and
exhibit one of the highest ratios of migrants to nationals in the
world. More than half of the regional population is expatriate
(55.9%).7 In Kuwait, Qatar, and UAE, non-nationals comprise more
than three-fourths of the population.7
The aim of this study was to characterize the epidemiology of
HCV in the Arabian Gulf by delineating HCV prevalence among the
different risk groups in each of the six countries and by estimating
the country-speciﬁc HCV population-level prevalence among
nationals as well as the entire resident population of nationals
and expatriates. The study was conducted under the umbrella of
the MENA HCV Epidemiology Synthesis Project, an ongoing effort
to characterize the epidemiology of HCV in the MENA region.4,8–10ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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necessary for policy-makers and public health stakeholders to set
the key research, policy, and programming priorities for the MENA
region.
2. Methods
The study methodology was developed based on an adaptation
of a recently published protocol for conducting systematic reviews
and meta-analyses of HCV in the Horn of Africa subregion of
MENA.9,11 The main features of this methodology are described
below.
2.1. Data sources and search strategy
The systematic review was conducted on the basis of the items
outlined in the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidelines.12 The study objective was
to assess HCV antibody prevalence (seroprevalence) and incidence
(seroincidence) in the different population groups in the six
countries of the Gulf Region: Bahrain, Kuwait, Oman, Qatar, Saudi
Arabia, and UAE.13 The PRISMA checklist can be found in the
Supplementary Material (SM 1). The main data sources were the
PubMed and Embase databases (accessed February 2, 2015), which
were searched using both MeSH/Emtree terms and text terms, with
no time or language restrictions. MeSH/Emtree terms were exploded
to cover all subheadings. Details of the search criteria for each of
these databases can be found in the Supplementary Material (SM
2). Additional sources of data were primarily obtained through the
MENA HIV/AIDS Epidemiology Synthesis Project database.14,15
These included the gray literature, such as country-level reports.
2.2. Study selection
Search results were imported into the reference manager,
Endnote, where duplicate publications were identiﬁed and
excluded. The titles and abstracts of all records retrieved were
screened for relevance independently by two of the authors (YM
and SR). This involved screening all titles and abstracts to exclude
all non-relevant articles. The full texts of all articles deemed
relevant or potentially relevant after the initial screening were
then retrieved and screened. Inconsistencies between reviewers
were discussed and resolved by consensus.
A publication was considered eligible for inclusion in the review
if it was conducted in any of the six countries included and had data
on at least one of the following outcomes of interest: (1) prevalence
of HCV as detected by HCV antibodies, and (2) incidence of HCV as
detected by HCV antibodies. Only studies reporting primary data
were included. Reviews of the literature were excluded, but all data
reported in them were checked and compared to the present search
results. Any additional study identiﬁed in reviews and not retrieved
by the present search was added. Editorials, case notiﬁcations, and
case series were excluded. All other study designs were eligible for
inclusion. A distinction was made between the number of reports
(published documents, i.e., papers, conference abstracts, or country-
level reports) and the number of outcomes. A report could contribute
more than one outcome measure. Outcomes in more than one
population/setting within a report were included separately.
Outcomes duplicated in more than one report were included only
once. Results were synthesized into one list containing all eligible
unique outcome measures.
2.3. Data extraction and population classiﬁcation
The following data were then extracted from each relevant
report included in the review: reference details (author, title,journal, year of publication), country, city/region, study design,
sampling technique, study population, socio-demographic char-
acteristics of the population, sample size, number of individuals
tested for HCV (if different from the sample size), number of
individuals who tested positive, and the reported prevalence and
incidence of HCV. Data on HCV RNA prevalence among study
population(s) were also extracted from relevant studies whenever
available.
Extracted data were then classiﬁed and analyzed on the basis of
the study population’s risk of acquiring HCV. The four deﬁned major
population risk groups are the following: (1) populations at high
risk,4,8 including multi-transfused patients such as thalassemics,
hemodialysis patients, and people who inject drugs (PWID), among
others; (2) populations at intermediate risk,4,8 including familial
contacts to HCV patients (i.e., their children, spouses, and other
household contacts), select practitioners of professions at risk of
HCV (such as healthcare workers (HCWs) and medical students), and
populations with health facility/injecting exposures (such as
diabetic patients and hospitalized populations); (3) general
population groups (populations at low risk of HCV exposure),4,8
including pregnant women, blood donors, children, college students,
individuals undergoing pre-marital blood screening, expatriate
workers undergoing mandatory pre-employment screening, outpa-
tient clinic attendees, and other general population groups (such as
populations deﬁned in studies as simply healthy populations, or
healthy organ donors); and (4) special clinical population groups,4,8
such as hepatocellular carcinoma patients (HCC), viral hepatitis
patients, lichen planus patients, schistosomiasis patients, and
chronic liver disease (CLD) patients, among others. This ﬁnal
category includes patients with speciﬁc diseases that are associated
with HCV infection, or patients requiring clinical attention and who
could thus be exposed to HCV at medical care facilities, but at
variable levels of exposure risk that are difﬁcult to categorize into
any of the other population groups mentioned.
2.4. Quantitative analysis
Analyses were conducted using R3.0.1 and Stata/SEv13. The
DerSimonian–Laird random-effects method was used to pool study
estimates.16 This method assumes that the true effect size is
normally distributed and could vary from one study to another,17
thus accounting for both sampling variation and heterogeneity in
effect size. Effect sizes of individual measures were weighted by
their inverse variance. The variance was stabilized using the
Freeman–Tukey type arcsine square-root transformation.18 Back-
transformed pooled proportions were then calculated using
Miller’s inverse transformation with the harmonic mean of the
sample sizes.19 The I2 value and its conﬁdence interval (CI) were
calculated to examine the magnitude of the variation between
measures due to heterogeneity rather than chance.20 A two-sided
probability value of <0.10 was considered as signiﬁcant.9
As a main objective was to estimate the country-speciﬁc HCV
population-level prevalence in each of the six countries for which
sufﬁcient data were available, only HCV prevalence measures of
general population groups were included in this analysis. The
prevalence measures were stratiﬁed by country and then stratiﬁed
further into prevalence measures among nationals only and
measures including the entire resident populations, i.e. both
nationals and expatriates. Stratiﬁcation by expatriates only could
not be done since few reports provided this information. For
outcome measures missing either the number of individuals tested
for HCV antibodies (denominator) or the number of individuals
testing anti-HCV positive (numerator), but reporting HCV preva-
lence, missing values were calculated using the available
information. The 95% CI were estimated for each pooled mean
prevalence.
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prevalence measure was included whether nationality was stated,
unstated, or a mixture of nationalities was implied. In the absence
of stratiﬁcation in a study sample, the overall outcome measure
was included. For reports with both stratiﬁcations and overall
measures, for example overall prevalence in the sample and also
prevalence stratiﬁed by sex and prevalence stratiﬁed by year, the
prevalence stratiﬁed by sex was selected for inclusion because of
the greater epidemiological relevance. In doing so the other two
measures (overall and by year) were excluded to avoid bias arising
from the duplication of measures from the same population.
Since there was a large number of reported HCV prevalences for
Saudi Arabia, a meta-analysis was conducted to estimate HCV
prevalence in the different geographic regions of this country. This
analysis included only reports in which the city or region
information was available. Reports with information on cities
and not regions were classiﬁed into their respective regions as
deﬁned by Al-Faleh et al.21
3. Results
3.1. Search results
A schematic diagram of the study selection process can be seen
in Figure 1, as adapted from the PRISMA 2009 ﬂow diagram.12 A
total 723 records were identiﬁed (321 through PubMed and
402 through Embase) as of February 2, 2015. Of these records,
254 were excluded as duplicates. On assessing all documents for
eligibility, the full texts of 199 records were identiﬁed for full-text
screening, in addition to two records identiﬁed through the723 ci tati ons identi fie d through data base 
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Figure 1. Flow of article selection for the hepatitis C virus (Hreferences of reviews and four country-level reports identiﬁed
through the MENA HIV/AIDS Synthesis Project database. Of these
records, 159 reports were found to be relevant and were included
in this study.
3.2. HCV prevalence overview
Data on HCV prevalence as well as other indicators were
abstracted from the 159 relevant reports. Details of all outcome
measures are given in the Supplementary Material (tables SM 3–
6). In total, 556 prevalence measures were identiﬁed in this study.
Most measures presenting HCV prevalence in the region were from
Saudi Arabia (n = 442), followed by Kuwait (n = 43), UAE (n = 30),
Qatar (n = 23), Oman (n = 12), and Bahrain (n = 6). The populations
studied ranged from general population groups (n = 335), to high-
risk groups (n = 112), intermediate-risk groups (n = 47), and
special clinical populations (n = 61). The majority of studies
followed a cross-sectional design (90%) and relied on convenience
sampling (93%). Study sample sizes and sex distributions varied.
3.2.1. Bahrain
Three reports indicated HCV prevalence in Bahrain among high-
risk populations or special clinical populations (Figure 2B;
Supplementary Material 7B). HCV prevalence among hemodialy-
sis patients was between 7.4% and 9.24%. A study by Al-Mahroos
and Ebrahim published in 1995, conducted among children with
hemolytic anemia, found HCV prevalence to be 40% among
children who had undergone at least one transfusion and 2%
among those with no history of transfusion.22 Two studies were
conducted in general population groups (Figure 3B). Both studies sea rching 
40 2) 
254 duplica tes  re move d 
 identifie d 
276 citatio ns exclu ded  th roug h 
title and abstract  scree ning 
ified  for 
40 articles  exclud ed:  
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Selected on  HCV:  5 
Uncle ar:  1 
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Review:  1 
Duplicate  studies:  8  
ic review   
CV) prevalence and incidence in the Arabian Gulf search.
Figure 2. Distribution of hepatitis C virus (HCV) prevalence among high-risk groups in the Arabian Gulf countries. (A) HCV prevalence in the different high-risk groups in Saudi
Arabia. (B) HCV prevalence in the high-risk groups of the remaining ﬁve Arabian Gulf countries: Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates. Few studies
stratiﬁed by sub-groups were identiﬁed for countries other than Saudi Arabia; they were, therefore, grouped together in panel B.
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donors and reported a low prevalence of 0.3%.23,24
3.2.2. Saudi Arabia
Saudi Arabia is the largest country in the region by population
and area. Of the 442 HCV prevalence measures from this country
reported in 120 records, 81 were among high-risk populations,
32 among intermediate-risk populations, 60 among special clinical
populations, and 269 among general populations.
Figure 2A depicts the range of HCV prevalence among the
different high-risk population subgroups in Saudi Arabia. HCV
prevalence in hemodialysis patients ranged from 4.8% to as high as
84.6%. Among multi-transfused patients, HCV prevalence ranged
between 4.6% and 78.6%. The lowest HCV prevalence (4.6%) was
reported in a recent study by Zaher and Adam, which was
conducted among multi-transfused children with a mean age of
12.9 years.25 A majority of the studies conducted among
thalassemics in Saudi Arabia also involved children and young
adults. HCV prevalence among thalassemics was between 4.6% and
70%.
Five studies conducted among PWID in Saudi Arabia were
identiﬁed. HCV prevalence ranged between 14.4% and 74.6%. The
most recent study, estimating the prevalence in a combined
population of injecting and non-injecting drug users, reported a
prevalence of 35.6% and RNA prevalence of 29.9%.26
Supplementary Material SM 7 depicts the range of HCV
prevalence among intermediate-risk and special clinical popula-
tions in Saudi Arabia. Among populations at intermediate risk, Arif
et al. reported a prevalence of 0% in household contacts of HCVpatients without CLD compared to 1.6% among household contacts
of HCV patients with CLD.27 Hospital attendees had a prevalence
between 0.2% and 22.5%. The prevalence varied with age and
nationality, with the highest prevalence observed among the 45–
54-year-olds (15%) and among Egyptians (22.5%). HCV prevalence
among HCWs ranged from 0% to 3.2%. Two studies reported HCV
prevalence in populations with sexually transmitted diseases,
reporting a high prevalence of 12%28 and 15.9%.29
High HCV prevalence was observed among special clinical
populations. HCV prevalence among acute viral hepatitis patients
ranged from 0% to 74.4%. Prevalence among HCC patients was
between 4.4% and 62%, among non-Hodgkin’s lymphoma patients
was between 0% and 21%, and among lichen planus patients was
between 9.8% and 26.3%. A study conducted in children 1–12 years
of age undergoing chemotherapy reported a high prevalence of
11.3%.30 Only one study investigated HCV prevalence among
schistosomiasis patients.31 HCV prevalence in the overall study
population was 18.0%: 11.8% among Saudi patients, 26.7% among
Egyptian patients, and 14.3% among patients of other Middle
Eastern nationalities.31
There is large variability in HCV prevalence among the
different general population groups in Saudi Arabia. The
prevalence ranged from 0% to 34.0% (Figure 3). Among blood
donors, HCV prevalence was between 0% and 34.0%. Prevalence
among pregnant women in two studies was 0.1%32 and 4.6%,29
and among college students was between 0.03% and 0.4%. Higher
HCV prevalence was observed among expatriates living in Saudi
Arabia than among Saudi nationals (Figure 3, Supplementary
Material 8A). Supplementary Material SM 8B depicts the range
Figure 3. Distribution of hepatitis C virus (HCV) prevalence among general population groups in the Arabian Gulf countries. (A) Among country nationals only for countries
from which this information was available. (B) Among the entire resident populations of nationals and expatriates.
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was available. Egyptians had by far the highest HCV prevalence,
reported at 8.0% to 34.0%, followed by Saudis at 0.2% to 7.3% and
Indians at 0% to 7.1%.
3.2.3. Kuwait
Nine reports estimated HCV prevalence in different population
groups in Kuwait, four of which reported the prevalence among
high-risk populations. Figure 2B depicts the range of HCV
prevalence in high-risk populations in Kuwait. A high prevalence
was observed among hemodialysis patients, ranging between 27%
and 71% (Figure 2B). Only one study was conducted among
thalassemic patients, reporting a prevalence of 33%.33
With regard to the populations at intermediate risk, Chehadeh
et al. noted a prevalence of 7% among diabetics.34 Only one study
was conducted among HCWs, reporting a prevalence of 0.9%.35
High HCV prevalence was observed among special clinical
populations, ranging from 5.6% to 60.6%. Supplementary Material
SM 7 depicts the range of HCV prevalence among intermediate-risk
and special clinical populations in Kuwait.
With regard to the general population groups, HCV prevalence
among blood donors ranged from 0.1% to 14.0% (Figure 3). Overall,a lower prevalence was observed among Kuwaiti nationals
compared to expatriates residing in the country (Figure 3,
Supplementary Material SM 8A). In a recent study conducted
among 8561 Kuwaiti and 4237 non-Kuwaiti Arab ﬁrst-time blood
donors, HCV prevalence was 0.8% among Kuwaitis and 5.4% among
non-Kuwaiti Arabs.36
3.2.4. Oman
Seven articles reported HCV prevalence in Oman, two of which
reported on high-risk populations (Figure 2B). The ﬁrst study was
among hemodialysis patients and reported a prevalence of 26.5%.37
The second was among PWID and reported a prevalence of 48.05%,
but the prevalence was based on self-report.38
No HCV was detected in a study conducted among medical
students.39 A recent study conducted in a special clinical
population group (immune thrombocytopenia patients) reported
a prevalence of 3.1%.40 Supplementary Material SM 7 depicts the
range of HCV prevalence among intermediate-risk and special
clinical populations in Oman.
Overall, HCV prevalence among the general population groups
in Oman, nationals and expatriates, was below 1%, ranging
between 0.4% and 0.9% in blood donors (Figure 3B).
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Of eight reported studies estimating HCV prevalence in Qatar,
only one was conducted in a high-risk population (Figure 2B). The
study reported a high HCV prevalence of 44.6% among hemodialy-
sis patients.41
High HCV prevalence was also reported among special clinical
population groups, with a range of 9% to 30.6%. A recent study by Al
Mannai and Riad reported a prevalence of 9% among lichen planus
patients.42 Khan et al. reported a prevalence of 25.8% among
cirrhosis patients.43 Supplementary Material SM 7B depicts the
range of HCV prevalence among special clinical populations in
Qatar.
Four reports indicated HCV prevalence in general population
groups in Qatar. Two studies were conducted among blood donors of
different nationalities. Overall, HCV prevalence among general
population groups, nationals and expatriates, ranged from 0.3% to
11.2% (Figure 3). Supplementary Material SM 8A compares HCV
prevalence between Qatari nationals and expatriate residents for a
number of studies for which this information was available.
Variation in HCV prevalence between Qatari nationals and expatri-
ate residents was reported in two studies.44,45 The overall HCV
prevalence among 3352 blood donors was 2.8%, however the
prevalence was only 0.4% among the Qatari blood donor subgroup.44
Similarly, Fawzi et al. reported a 0.5% HCV prevalence among Qatari
and 1.9% among non-Qatari blood donors, with the highest
prevalence being reported among Egyptian blood donors (11.2%).45
3.2.6. United Arab Emirates
Twelve reports measuring HCV prevalence in UAE were
identiﬁed, of which three reported the HCV prevalence among
high-risk population groups. Figure 2B depicts the range of HCV
prevalence in high-risk populations in UAE. One study was
conducted among hemodialysis patients and reported a prevalence
of 24.4%.46 A high HCV prevalence of 18.8% was reported among
thalassemic children.47
High HCV prevalence was also reported among intermediate-
risk groups and special clinical populations in UAE. A prevalence of
7.7% was reported in children of HCV-positive Egyptian women
residing in UAE, 73.9% in their spouses, and 26.8% in their other
household contacts.48 A recent study conducted by Abro et al.
reported a low HCV prevalence of 1.2% among acute viral hepatitis
patients.49 The prevalence was 0% among UAE nationals, but as
high as 50% among Pakistani nationals.49 The prevalence among
CLD patients was 43.7%.50 Supplementary Material SM 7 depicts
the range of HCV prevalence among intermediate-risk and special
clinical populations in UAE.
Figure 3 displays the distribution of HCV prevalence in the
general population groups in UAE for both nationals alone and
mixed populations of nationals and expatriates. Overall, HCV
prevalence in the general population groups ranged between 0%
and 13.5% (Figure 3). It was higher among expatriates compared to
nationals (Figure 3; Supplementary Material SM 8A). Newson-
Smith reported a prevalence of 4.5% among Egyptians and 0.8%
among other offshore gas and oil workers.51
3.3. HCV incidence overview
Only one study reported HCV incidence in the Arabian Gulf
region. The study, conducted in 1995, examined HCV incidence in a
dialysis unit in UAE and estimated it at 0.95 per 100 person-
months.46
3.4. Risk factors
Risk factors were most typically identiﬁed in studies conducted
among high-risk populations. These included dialysis patients andmulti-transfused patients. The main risk factors consistently cited
for HCV exposure were age,37,41,52–63 duration on dialysis,37,41,52–63
and the number of blood transfusions.22,53,54,56,60,61,64,65
3.5. HCV genotypes
Genotype 4 is the most common HCV genotype reported in
Saudi Arabia, Kuwait, and Qatar.66–69 According to a study by
Messina et al., HCV genotype 4 accounts for 48% of HCV infections
in Saudi Arabia, 56% of infections in Kuwait, and all infections in
Qatar (100%).67 In both Saudi Arabia and Kuwait, genotype 1 is the
second most frequent genotype.67 In Bahrain and UAE, however,
genotype 1 is the most common genotype, accounting for 67% of
HCV infections in Bahrain23,67 and almost 50% of infections in
UAE.67,70 Genotype 2 is the second most common genotype in
Bahrain,67 while genotype 3 is the second most common genotype
in UAE.67,70 No data on genotypes were available for Oman.67
3.6. National and regional population-level HCV prevalence estimates
Pooled HCV population-level prevalence estimates stratiﬁed by
country and nationality (nationals versus nationals and expatri-
ates) are presented in Table 1 and Figure 4A, B. For Gulf country
nationals alone in all countries for which information on
nationality was available, the pooled HCV prevalence estimate
for the whole region was 1.35% (95% CI 1.15–1.56). The pooled
country-speciﬁc prevalence estimate among nationals was 0.24%
(95% CI 0.02–0.63) for UAE, 0.44% (95% CI 0.29–0.62) for Kuwait,
0.51% (95% CI 0.43–0.59) for Qatar, and 1.65% (95% CI 1.40–1.91) for
Saudi Arabia. No data on nationality were available for Bahrain or
Oman, so no pooled estimates for nationals only could be
calculated. Supplementary Material SM 9–11 show forest plots
depicting the study-speciﬁc estimates as well as the meta-analysis
estimates for nationals only.
With the inclusion of all general population prevalence
measures regardless of nationality, the pooled HCV prevalence
estimate for the whole region, among the resident population of
nationals and expatriates, was 1.50% (95% CI 1.30–1.70). The
country-speciﬁc pooled HCV prevalence estimate, among the
resident population of nationals and expatriates, was 0.30% (95% CI
0.23–0.38) for Bahrain, 0.41% (95% CI 0.35–0.46) for Oman, 1.06%
(95% CI 0.51–1.81) for Qatar, 1.45% (95% CI 0.75–2.34) for Kuwait,
1.63% (95% CI 1.42–1.84) for Saudi Arabia, and 1.64% (95% CI 0.96–
2.49) for UAE. Supplementary Material SM 12–15 show forest
plots depicting the study-speciﬁc estimates as well as the meta-
analysis estimates for the entire resident populations.
Variations in HCV prevalence were observed in Saudi Arabia.
Figure 4C displays the pooled HCV prevalence estimates and 95% CI
for the ﬁve geographic regions of Saudi Arabia. A higher mean HCV
prevalence was observed among the populations residing in the
southwestern and southern parts of Saudi Arabia compared to the
other regions.
4. Discussion
This is the ﬁrst systematic review and data synthesis of HCV
epidemiology in the Arabian Gulf region. The national population-
level HCV prevalence in each of the Arabian Gulf countries was also
estimated. With the recent remarkable successes in HCV treat-
ment,71–74 these ﬁndings take on additional importance by
providing the evidence base necessary for health services planning
and the outlining of HCV policy guidelines, as well as the design
and implementation of HCV treatment and prevention programs.
The results presented here show that the overall HCV
prevalence in this region is at a level of about 1%, which is
comparable to prevalence levels observed globally, including those
Table 1
Pooled hepatitis C virus prevalence in general population groups for each of the Arabian Gulf countries, among nationals only and among the entire resident populations of
both nationals and expatriates
Category No. of data
points
No. of
reports
No. tested
for HCV
antibody
No. HCV
antibody-positive
HCV prevalence,
% (95% CI)
I2, % (95% CI) p-Valuea
Country nationals only
All countries 70 33 852 836 9223 1.35 (1.15–1.56) 98.1 (97.9–98.3) <0.001
Bahrainb - - - - - - -
Saudi Arabia 57 27 808 787 8994 1.65 (1.40–1.91) 98.4 (98.2–98.5) <0.001
Kuwait 9 2 12 853 67 0.44 (0.29–0.62) 39.9 (0.0–72.3) 0.10
Omanb - - - - - -
Qatar 2 2 29 764 157 0.51 (0.43–0.59) 0.0 (0.0–0.0) 0.81
United Arab Emirates 2 2 1432 5 0.24 (0.02–0.63) 0.0 (0.0–0.0) 0.50
Resident population (nationals and expatriates)
All countries 183 78 1 574 036 16 347 1.50 (1.30–1.70) 98.7 (98.6–98.8) <0.001
Bahrainc 2 2 21 125 63 0.30 (0.23–0.38) 0.0 (0.0–0.0) 0.96
Saudi Arabia 126 51 999 127 11 582 1.63 (1.42–1.84) 97.8 (97.6–97.9) <0.001
Kuwait 22 5 44 772 939 1.45 (0.75–2.34) 97.6 (97.1–98.1) <0.001
Oman 6 6 64 530 84 0.41 (0.35–0.46) 23.4 (0.0–67.4) 0.26
Qatar 16 4 153 704 2482 1.06 (0.51–1.81) 99.3 (99.2–99.4) <0.001
United Arab Emirates 11 10 290 778 865 1.64 (0.96–2.49) 99.4 (99.3–99.5) <0.001
HCV, hepatitis C virus; CI, conﬁdence interval.
a p-Value <0.10 considered statistically signiﬁcant, indicating that the variation between pooled measures is due to heterogeneity rather than chance.
b No studies provided numbers on HCV prevalence among nationals only.
c All studies for Bahrain included a study population that was a mix of Bahrainis and Saudis.
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prevalence was estimated at 1.4% among nationals and at 1.5%
among the resident population of nationals and expatriates. The
country-speciﬁc HCV prevalence among nationals ranged from as
low as 0.2% in UAE to as high as 1.7% in Saudi Arabia. By also including
the expatriate populations, the country-speciﬁc HCV prevalence
ranged from as low as 0.3% in Bahrain to as high as 1.6% in UAE.
The higher HCV prevalence estimates among some of the
expatriate populations in some of the countries appear to reﬂect
the higher HCV prevalence in the countries of origin of these
expatriates. For example, the high HCV prevalence of 34.0%76
among Egyptian blood donors in Saudi Arabia and 11.2%45 among
Egyptian blood donors in Qatar appears to reﬂect the high HCV
prevalence in Egypt. At 14.7%, Egypt has the highest HCV
prevalence worldwide.1,3 Exposure to the infection has probably
occurred in the countries of origin and not in the host countries.
This pattern has also been observed by Perumalswami et al.: in a
recent study conducted in New York City, they observed an HCV
prevalence of 15.6% among Egyptian-born persons living in New
York and a strong association between HCV exposure and the
number of years resident in Egypt.77 Although all Gulf countries
have mandated HCV screening prior to obtaining residency
permits, migrants who test positive for HCV antibody are not
necessarily deported. Moreover, those who became residents
before the introduction of mandatory screening in the mid 1990s
are usually allowed continuous residency even if found to be HCV
antibody-positive.
The distribution of HCV genotypes in this region appears also to
reﬂect in part the HCV genotype distributions in the expatriates’
countries of origin. Genotype 4 appears to be the most common
HCV genotype in most countries in this region, followed by
genotypes 1 and 3. HCV genotype 4 is by far the most common
genotype in Egypt and is common in other MENA countries such as
Iraq, Jordan, Lebanon, and Syria.10,66,67 Meanwhile, genotypes
1 and 3 are the most common genotypes in India, Nepal, and
Pakistan,66,67 and there are large expatriate populations from these
countries in the Arabian Gulf region. HCV genotype diversity
therefore appears also to suggest exposure in the countries of
origin.
The high HCV prevalence levels among some of the clinical
populations are indicative of exposure in the medical setting.Prevalence measures among hemodialysis patients ranged from
7.4%23 to as high as 84.6%.78 In the only incidence study identiﬁed
in the region, HCV incidence in a dialysis unit in UAE was high at
0.95 per 100 person-months.46 The main risk factors consistently
cited for exposure to the infection across studies were duration on
dialysis37,41,52–63 and history of blood transfusions.56,60,61,64,65
It is difﬁcult to ascertain the timing of exposure to HCV. It is
conceivable that a large proportion of exposures may have
occurred prior to the enforcement of stringent infection control
and blood screening protocols, which were implemented starting
in the 1990s. Regrettably, no nationally representative population-
based studies with age-stratiﬁed prevalence estimates could be
identiﬁed. Such studies may help identify changes in exposure to
the infection across different age cohorts at different times, such as
those identiﬁed in other countries.79–81 Regardless, there seems to
be an indication of ongoing HCV transmission in the clinical setting
that appears to be linked to less than optimal infection control
practices, as highlighted by the high HCV prevalence reported in
recent studies among children with a history of clinical proce-
dures.25,47
Injecting drug use is the major driver of HCV incidence and
prevalence in developed countries.82,83 The estimated population
proportion of PWID in the Arabian Gulf ranges between 0.16% in
Bahrain and 0.30% in each of Kuwait, Oman, and UAE.84 The
population proportion of PWID in the whole MENA region is
estimated at 0.24% – in the intermediate range compared to global
levels.84 There are few studies on HCV prevalence among PWID in
the Arabian Gulf region, some of which have included other drug
users; a study from Saudi Arabia reported HCV prevalence ranging
between 40.8% and 74.6%85 (Supplementary Material table SM 3).
Given the population proportion of PWID and the epidemiological
context of HCV infection as highlighted in this study, it does not
seem that injecting drug use explains more than a minority of HCV
exposures in this region.
Regional differences in HCV prevalence were identiﬁed in Saudi
Arabia (Figure 4C). The southwestern and southern regions of the
country are the two with the highest pooled HCV prevalence,
especially Gizan Province.21,86 Al-Faleh et al. conducted a
population-based survey of children (1 to 10 years of age) across
Saudi Arabia and reported a high HCV prevalence of 5.7% in the city
of Gizan, which was several fold higher than that of the rest of the
Figure 4. Pooled hepatitis C virus (HCV) prevalence and 95% conﬁdence intervals for
the general population groups of each of the six Arabian Gulf countries. (A) Among
country nationals only for countries from which this information was available. (B)
Among the entire resident populations of nationals and expatriates. (C) Among the
different regions in Saudi Arabia.
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a rather high prevalence of 3.4% among healthy adult controls in
Gizan.86 Gizan appears also to be hyperendemic for hepatitis B
virus,21 which shares overlapping epidemiology with HCV. While
the speciﬁc modes of HCV exposure are not clear, and most likely
they are medical-related exposures, the area of Gizan has been
linked to folk blood-letting practices (‘Hijama’) that can increase
the risk of blood-borne infections such as HCV.87 The regional
variations in prevalence in Saudi Arabia warrant further investi-
gation and determination of the speciﬁc modes of HCV exposure.
Among the limitations of this study are the variability in the
number of studies across countries and the low number of studies
from Bahrain and Oman. The general population studies included
in the meta-analyses may not have been representative of the
whole population. Nearly all studies included convenience
samples, and many of the studies were on blood donors.
Convenience sampling often leads to a biased estimate of infectionprevalence. For example, HCV prevalence in blood donors may
underestimate HCV prevalence in the whole population. It is
conceivable that there could be a selection bias towards lower risk
among blood donors, normally a healthy population. Future
studies should use probability-based sampling methods, such as
nationally representative population-based surveys, which would
help yield accurate estimates of HCV prevalence in this region and
identify the main risk factors of HCV exposure in the population.
These surveys would help to draw a clearer and more complete
picture of HCV epidemiology in this part of the world.
Genotype information was available from only a few studies,
and therefore the genotype distribution described may have been
biased by non-representative samples. The populations were
classiﬁed into high-risk, intermediate-risk, and general population
groups by convention.8 However, there is no established existing
classiﬁcation of risk for some populations, and the information
available in some studies was not sufﬁcient to determine the level
of risk. In these situations, the level of risk was determined based
on the authors’ best judgment of the risk of exposure to HCV
infection in this population. For example, clinical populations for
which the risk of exposure was uncertain were classiﬁed into the
independent category of ‘special clinical populations’.
The meta-analyses highlighted substantial heterogeneity
among the studies conducted in the general population groups.
This is not surprising considering the differences between studies
in terms of the populations studied, sampling methodology and
recruitment, sample age distribution, year of study, location, and
assay used.8 However, due to the relatively small number of
outcome measures for each country, it was not possible to conduct
a meaningful meta-regression analysis to identify the potential
sources of variation explaining the observed heterogeneity.
In conclusion, despite variability in HCV prevalence across the
Arabian Gulf countries, prevalence levels are similar to global
levels. HCV prevalence among nationals appears to be around 1%
and is generally lower than that among resident expatriate
populations. The high HCV prevalence found in speciﬁc expatriate
populations appears to reﬂect the higher prevalence in their
countries of origin. Ongoing transmission appears to be concen-
trated in high-risk groups and is often linked to medical care.
Injecting drug use is possibly a major contributor to HCV incidence
in this region, but is not likely to explain more than a minority of
prevalent infections.
These ﬁndings provide the evidence base necessary to inform
health services planning, the articulation of HCV policy guidelines,
and implementation of HCV programs to reduce transmission and
decrease the burden of disease. Further research is needed to draw
a more complete understanding of HCV epidemiology, such as
through nationally representative population-based surveys.
These surveys may identify modes of exposure, delineate spatial
variability in prevalence, and assess HCV knowledge and attitudes,
as has been done recently in Egypt. 3,79,88–91 This is particularly
relevant for Saudi Arabia, a large country where there appears to be
spatial variability in HCV exposure. Since HCV prevalence in the
Arabian Gulf countries is not high and is linked to speciﬁc settings,
HCV prevention efforts should be targeted at infection control in
the clinical setting and harm reduction among PWID.
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